Table of ContentsView AllTable of ContentsWhat Are Biologics?How Biologics Are UsedBenefits and RisksTreatment Procedures of Benlysta for LupusFrequently Asked Questions
Table of ContentsView All
View All
Table of Contents
What Are Biologics?
How Biologics Are Used
Benefits and Risks
Treatment Procedures of Benlysta for Lupus
Frequently Asked Questions
In the past 10 years, a new class of drug called biologics (sometimes called biological medical therapy) has led to new, successful treatments for lupus and other inflammatory diseases. Biologics for lupus include Benlysta (belimumab) as well as many biologics being tested in clinical trials.
Verywell / Jessica Olah
Additional types of lupus revolve around the various organs that are most impacted, including:
Biologics are being tested for many of these forms of lupus, but the only approved biologic treatment for lupus, Benlysta, is approved only for SLE and lupus nephritis.
This article will define the types of biologics being tested to treat lupus, the specific drugs used for lupus treatment, and the benefits and risks of these types of treatments.
Biologicsare a type of treatment new to the market over the last few decades. These drugs are genetically engineered proteins based on the body’s natural proteins and use live systems to manufacture them. Biologics target specific areas of the immune system that cause inflammation.
Biologics have many names. They may be called “biologic therapy,” “biological therapy,” “biologicals,” or “biopharmaceuticals.” They include a large class of drugs made up of many different types.
The types of biologics that are approved and being tested for treating lupus fall into three specific categories.
They have special arms with sections that are custom-made to match up with specific proteins on invaders like viruses and bacteria. When antibodies bind to these invaders, they send signals to the rest of the body to attack the invaders. These custom arms can be made in the lab to attach to and mark many different proteins, not just those from germs.
Three specific technologies are being used to treat lupus:
Two other types of biologics in testing for lupus are:
How Biologics Can Be Used to Treat Lupus
Before Benlysta was approved in 2011, there had been a 50-year lull in new treatments for lupus. The only approved drugs for SLE had been Plaquenil (hydroxychloroquine), prednisone (a corticosteroid used to reduce inflammation), and aspirin.
These and other drugs that had been used off-label for lupus are general immune system dampeners. They suppress the entire immune system, not just the parts that act up.
But biologics like Benlysta are targeted treatments. They can turn down just specific parts of the immune system that lead to inflammation or specific autoimmune responses that lead to other symptoms of lupus.
Benlysta, specifically, turns down a protein that stimulates B-cells. B-cells are a type of white blood cell that make antibodies. In lupus, these cells attack and damage the body’s healthy tissues instead of hunting down viruses or bacteria.
Off-Label Biologics and Clinical Trials
Rituxan (rituximab)is a monoclonal antibody approved to treat blood cancers, rheumatoid arthritis, and several other conditions.It is used (rarely) off-label for systemic lupus erythematosus.
It works similarly to Benlysta and is being tested for long-term treatment of systemic lupus to prevent flare-ups, times when disease symptoms are present.Original clinical trials of Rituxan weren’t successful in meeting their goals but did meet secondary goals and seem to show effectiveness in certain subsets of lupus patients.
Anifrolumabis a monoclonal antibody treatment specifically designed for lupus that was recently FDA-approved after completing its phase 3 clinical trials.
Clinical TrialsInclinical trials, treatments are given to patients and the effects and safety of the treatments are studied. Phase 1 trials focus on safety. Phase 2 trials check for effectiveness. Phase 3 trials compare the safety and effectiveness with standard treatments. After these, the drug may be evaluated for FDA approval.
Clinical Trials
Inclinical trials, treatments are given to patients and the effects and safety of the treatments are studied. Phase 1 trials focus on safety. Phase 2 trials check for effectiveness. Phase 3 trials compare the safety and effectiveness with standard treatments. After these, the drug may be evaluated for FDA approval.
Biologics approved for other conditions that are being studied in clinical trials for patients with various forms of lupus include:
New biologics for lupus that have not been approved yet but are being tested in clinical trials include:
Benefits and Risks of Biologics for Lupus
When used in addition to traditional lupus therapies, Benlysta has shown to be safe and effective at helping decrease symptoms of lupus without increasing side effects.It can even help lupus patients use fewer steroids like prednisone. Thesecorticosteroidscan lead to bone loss and organ damage when used for a long time.
There are risks from these drugs, specifically side effects, including the potential for an allergic reaction. It’s also possible they just won’t work well for you. Many clinical trials of biologics for lupus have failed to show the desired effects.
How Biologic Therapy Works
There are two ways to take Benlysta. You can get it as an infusion through a vein at a clinic, or you can use aself-injecting deviceto administer the dose at home.
If you get the drug as an intravenous (IV) infusion, you’ll need to go to an infusion clinic, hospital, or doctor’s office. Your healthcare provider will place a needle into a vein in your arm connected to a tube that will drip the medicine slowly for about an hour.
When you first start Benlysta infusions, you’ll go in every two weeks for the first three infusions. From then on, you’ll only need to go in once every four weeks.
If you choose to administer your injections at home, you’ll likely need some training from your doctor to ensure you’re doing it right.
The injector delivers the antibody drug under the skin while you’re at home. Prefilled syringes require you to insert a needle and press down the plunger to administer the medication, but they may be cheaper.
You’ll need to inject the medicine either into your abdomen or your thighs. Doses should be given once a week, every week. You’ll need a sharps container for safe disposal.
For many people, self-injecting is easier and more convenient than going to a clinic. Others prefer the IV route if they’re fearful of needles, squeamish about self-injecting, or don’t want to do it every week.
Whichever way you choose to take Benlysta, you may experience side effects. These include:
These side effects are typically mild, but it’s possible that you could sustain an allergic reaction that makes it hard to breathe. If that happens, call 911 immediately.
You’ll likely continue with your regular treatments while taking Benlysta. It may take weeks or months for the drug to start working. At that point, you can discuss with your doctor the option of going without some of your other drugs.
Summary
A Word From Verywell
Lupus can be a difficult disease to manage. Talk to your doctor about the risk and benefits of using biologics to treat your lupus. Many people find relief using Benlysta, though there are side effects. Your doctor may suggest you enroll in a clinical trial of other biologics being developed and tested.
Frequently Asked QuestionsMany biologics have been developed to treat inflammatory and autoimmune disorders. Only Benlysta is approved for lupus.The only approved biologic for lupus, Benlysta, is a monoclonal antibody that inhibits B-cells that produce antibodies that attack the body. Rarely, doctors prescribe Rituxan off-label. It is also a monoclonal antibody.
Many biologics have been developed to treat inflammatory and autoimmune disorders. Only Benlysta is approved for lupus.
The only approved biologic for lupus, Benlysta, is a monoclonal antibody that inhibits B-cells that produce antibodies that attack the body. Rarely, doctors prescribe Rituxan off-label. It is also a monoclonal antibody.
39 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.U.S. National Library of Medicine.Systemic lupus erythematosus.Samotij D, Reich A.Biologics in the treatment of lupus erythematosus: A critical literature review.Biomed Res Int. 2019;2019:8142368. doi:10.1155/2019/8142368Food and Drug Administration.Benlysta (belimumab) injection, for intravenous use. Benlysta (belimumab) subcutaneous use.Stohl W, Hilbert DM.The discovery and development of belimumab: the anti-BLyS–lupus connection.Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi:10.1038/nbt.2076Wise LM, Stohl W.Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents.Front Med (Lausanne). 2020;7:303. doi:10.3389/fmed.2020.00303Rydén-Aulin M, Boumpas D, Bultink I, et. al.Off-label use of rituximab for systemic lupus erythematosus in Europe.Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi:10.1136/lupus-2016-000163ClinicalTrials.gov.Efficacy of individualized rituximab in maintaining remission of moderate and severe systemic lupus erythematosus.AstraZeneca.SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus.Alexion.ULTOMIRIS® (ravulizumab‑cwvz).ClinicalTrials.gov.Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).Cosentyx.COSENTYX® (secukinumab).ClinicalTrials.gov.A study to assess the safety and efficacy of secukinumab in alleviating symptoms of discoid lupus erythematosus.ClinicalTrials.gov.Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE).Tremfya.Official consumer website for TREMFYA® (guselkumab).ClinicalTrials.gov.A study of guselkumab in participants with active lupus nephritis (ORCHID-LN).Darzalex.DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) & DARZALEX® (daratumumab).ClinicalTrials.gov.Daratumumab to treat active lupus nephritis.ClinicalTrials.gov.A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR).ClinicalTrials.gov.Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE).Omeros.Narsoplimab (OMS721; MASP-2 inhibitor, lectin pathway).ClinicalTrials.gov.Safety study of IgAN, LN, MN, & C3 glomerulopathy including dense deposit disease treated with OMS721.ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.Tanaka Y, Tummala R.Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.Mod Rheumatol. 2021;31(1):1-12. doi:10.1080/14397595.2020.1812201ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.BioSpace.Viela Bio announces final results from phase 1b trial of VIB7734 in patients with cutaneous lupus erythematosus.ClinicalTrials.gov.A phase 2 of VIB7734 for the treatment of moderate to severely active SLE (RECAST SLE).ClinicalTrials.gov.Efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.ClinicalTrials.gov.Efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE).Nektar.Nektar Therapeutics initiates clinical study of NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders.ClinicalTrials.gov.A study of LY3471851 in adults with systemic lupus erythematosus (SLE) (ISLAND-SLE).Alpine Immune Sciences.ALPN-101ClinicalTrials.gov.ALPN-101 in systemic lupus erythematosus (Synergy).BioGen.UCB and Biogen announce topline results from a phase 2b study of dapirolizumab pegol in systemic lupus erythematosus | Biogen.ClinicalTrials.gov.A study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS GO).ClinicalTrials.gov.Exploring the efficacy and safety of CS20AT04 (allogenic bone marrow-derived stem cell) in systemic lupus erythematosus patients.BioGen.Biogen announces first patient dosed in phase 3 systemic lupus erythematosus study | Biogen.Clinicaltrials.gov.A study to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus receiving background nonbiologic lupus standard of care (TOPAZ-1).MedlinePlus.Belimumab Injection.Benlysa.For subcutaneous use – BENLYSTA injection.
39 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.U.S. National Library of Medicine.Systemic lupus erythematosus.Samotij D, Reich A.Biologics in the treatment of lupus erythematosus: A critical literature review.Biomed Res Int. 2019;2019:8142368. doi:10.1155/2019/8142368Food and Drug Administration.Benlysta (belimumab) injection, for intravenous use. Benlysta (belimumab) subcutaneous use.Stohl W, Hilbert DM.The discovery and development of belimumab: the anti-BLyS–lupus connection.Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi:10.1038/nbt.2076Wise LM, Stohl W.Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents.Front Med (Lausanne). 2020;7:303. doi:10.3389/fmed.2020.00303Rydén-Aulin M, Boumpas D, Bultink I, et. al.Off-label use of rituximab for systemic lupus erythematosus in Europe.Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi:10.1136/lupus-2016-000163ClinicalTrials.gov.Efficacy of individualized rituximab in maintaining remission of moderate and severe systemic lupus erythematosus.AstraZeneca.SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus.Alexion.ULTOMIRIS® (ravulizumab‑cwvz).ClinicalTrials.gov.Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).Cosentyx.COSENTYX® (secukinumab).ClinicalTrials.gov.A study to assess the safety and efficacy of secukinumab in alleviating symptoms of discoid lupus erythematosus.ClinicalTrials.gov.Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE).Tremfya.Official consumer website for TREMFYA® (guselkumab).ClinicalTrials.gov.A study of guselkumab in participants with active lupus nephritis (ORCHID-LN).Darzalex.DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) & DARZALEX® (daratumumab).ClinicalTrials.gov.Daratumumab to treat active lupus nephritis.ClinicalTrials.gov.A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR).ClinicalTrials.gov.Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE).Omeros.Narsoplimab (OMS721; MASP-2 inhibitor, lectin pathway).ClinicalTrials.gov.Safety study of IgAN, LN, MN, & C3 glomerulopathy including dense deposit disease treated with OMS721.ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.Tanaka Y, Tummala R.Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.Mod Rheumatol. 2021;31(1):1-12. doi:10.1080/14397595.2020.1812201ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.BioSpace.Viela Bio announces final results from phase 1b trial of VIB7734 in patients with cutaneous lupus erythematosus.ClinicalTrials.gov.A phase 2 of VIB7734 for the treatment of moderate to severely active SLE (RECAST SLE).ClinicalTrials.gov.Efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.ClinicalTrials.gov.Efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE).Nektar.Nektar Therapeutics initiates clinical study of NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders.ClinicalTrials.gov.A study of LY3471851 in adults with systemic lupus erythematosus (SLE) (ISLAND-SLE).Alpine Immune Sciences.ALPN-101ClinicalTrials.gov.ALPN-101 in systemic lupus erythematosus (Synergy).BioGen.UCB and Biogen announce topline results from a phase 2b study of dapirolizumab pegol in systemic lupus erythematosus | Biogen.ClinicalTrials.gov.A study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS GO).ClinicalTrials.gov.Exploring the efficacy and safety of CS20AT04 (allogenic bone marrow-derived stem cell) in systemic lupus erythematosus patients.BioGen.Biogen announces first patient dosed in phase 3 systemic lupus erythematosus study | Biogen.Clinicaltrials.gov.A study to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus receiving background nonbiologic lupus standard of care (TOPAZ-1).MedlinePlus.Belimumab Injection.Benlysa.For subcutaneous use – BENLYSTA injection.
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
U.S. National Library of Medicine.Systemic lupus erythematosus.Samotij D, Reich A.Biologics in the treatment of lupus erythematosus: A critical literature review.Biomed Res Int. 2019;2019:8142368. doi:10.1155/2019/8142368Food and Drug Administration.Benlysta (belimumab) injection, for intravenous use. Benlysta (belimumab) subcutaneous use.Stohl W, Hilbert DM.The discovery and development of belimumab: the anti-BLyS–lupus connection.Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi:10.1038/nbt.2076Wise LM, Stohl W.Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents.Front Med (Lausanne). 2020;7:303. doi:10.3389/fmed.2020.00303Rydén-Aulin M, Boumpas D, Bultink I, et. al.Off-label use of rituximab for systemic lupus erythematosus in Europe.Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi:10.1136/lupus-2016-000163ClinicalTrials.gov.Efficacy of individualized rituximab in maintaining remission of moderate and severe systemic lupus erythematosus.AstraZeneca.SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus.Alexion.ULTOMIRIS® (ravulizumab‑cwvz).ClinicalTrials.gov.Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).Cosentyx.COSENTYX® (secukinumab).ClinicalTrials.gov.A study to assess the safety and efficacy of secukinumab in alleviating symptoms of discoid lupus erythematosus.ClinicalTrials.gov.Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE).Tremfya.Official consumer website for TREMFYA® (guselkumab).ClinicalTrials.gov.A study of guselkumab in participants with active lupus nephritis (ORCHID-LN).Darzalex.DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) & DARZALEX® (daratumumab).ClinicalTrials.gov.Daratumumab to treat active lupus nephritis.ClinicalTrials.gov.A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR).ClinicalTrials.gov.Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE).Omeros.Narsoplimab (OMS721; MASP-2 inhibitor, lectin pathway).ClinicalTrials.gov.Safety study of IgAN, LN, MN, & C3 glomerulopathy including dense deposit disease treated with OMS721.ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.Tanaka Y, Tummala R.Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.Mod Rheumatol. 2021;31(1):1-12. doi:10.1080/14397595.2020.1812201ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.BioSpace.Viela Bio announces final results from phase 1b trial of VIB7734 in patients with cutaneous lupus erythematosus.ClinicalTrials.gov.A phase 2 of VIB7734 for the treatment of moderate to severely active SLE (RECAST SLE).ClinicalTrials.gov.Efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.ClinicalTrials.gov.Efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE).Nektar.Nektar Therapeutics initiates clinical study of NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders.ClinicalTrials.gov.A study of LY3471851 in adults with systemic lupus erythematosus (SLE) (ISLAND-SLE).Alpine Immune Sciences.ALPN-101ClinicalTrials.gov.ALPN-101 in systemic lupus erythematosus (Synergy).BioGen.UCB and Biogen announce topline results from a phase 2b study of dapirolizumab pegol in systemic lupus erythematosus | Biogen.ClinicalTrials.gov.A study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS GO).ClinicalTrials.gov.Exploring the efficacy and safety of CS20AT04 (allogenic bone marrow-derived stem cell) in systemic lupus erythematosus patients.BioGen.Biogen announces first patient dosed in phase 3 systemic lupus erythematosus study | Biogen.Clinicaltrials.gov.A study to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus receiving background nonbiologic lupus standard of care (TOPAZ-1).MedlinePlus.Belimumab Injection.Benlysa.For subcutaneous use – BENLYSTA injection.
U.S. National Library of Medicine.Systemic lupus erythematosus.
Samotij D, Reich A.Biologics in the treatment of lupus erythematosus: A critical literature review.Biomed Res Int. 2019;2019:8142368. doi:10.1155/2019/8142368
Food and Drug Administration.Benlysta (belimumab) injection, for intravenous use. Benlysta (belimumab) subcutaneous use.
Stohl W, Hilbert DM.The discovery and development of belimumab: the anti-BLyS–lupus connection.Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi:10.1038/nbt.2076
Wise LM, Stohl W.Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents.Front Med (Lausanne). 2020;7:303. doi:10.3389/fmed.2020.00303
Rydén-Aulin M, Boumpas D, Bultink I, et. al.Off-label use of rituximab for systemic lupus erythematosus in Europe.Lupus Sci Med. 2016 Sep 6;3(1):e000163. doi:10.1136/lupus-2016-000163
ClinicalTrials.gov.Efficacy of individualized rituximab in maintaining remission of moderate and severe systemic lupus erythematosus.
AstraZeneca.SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus.
Alexion.ULTOMIRIS® (ravulizumab‑cwvz).
ClinicalTrials.gov.Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).
Cosentyx.COSENTYX® (secukinumab).
ClinicalTrials.gov.A study to assess the safety and efficacy of secukinumab in alleviating symptoms of discoid lupus erythematosus.
ClinicalTrials.gov.Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE).
Tremfya.Official consumer website for TREMFYA® (guselkumab).
ClinicalTrials.gov.A study of guselkumab in participants with active lupus nephritis (ORCHID-LN).
Darzalex.DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) & DARZALEX® (daratumumab).
ClinicalTrials.gov.Daratumumab to treat active lupus nephritis.
ClinicalTrials.gov.A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR).
ClinicalTrials.gov.Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE).
Omeros.Narsoplimab (OMS721; MASP-2 inhibitor, lectin pathway).
ClinicalTrials.gov.Safety study of IgAN, LN, MN, & C3 glomerulopathy including dense deposit disease treated with OMS721.
ClinicalTrials.gov.Study the efficacy and safety of VAY736 and CFZ533 in SLE patients.
Tanaka Y, Tummala R.Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.Mod Rheumatol. 2021;31(1):1-12. doi:10.1080/14397595.2020.1812201
BioSpace.Viela Bio announces final results from phase 1b trial of VIB7734 in patients with cutaneous lupus erythematosus.
ClinicalTrials.gov.A phase 2 of VIB7734 for the treatment of moderate to severely active SLE (RECAST SLE).
ClinicalTrials.gov.Efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
ClinicalTrials.gov.Efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE).
Nektar.Nektar Therapeutics initiates clinical study of NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders.
ClinicalTrials.gov.A study of LY3471851 in adults with systemic lupus erythematosus (SLE) (ISLAND-SLE).
Alpine Immune Sciences.ALPN-101
ClinicalTrials.gov.ALPN-101 in systemic lupus erythematosus (Synergy).
BioGen.UCB and Biogen announce topline results from a phase 2b study of dapirolizumab pegol in systemic lupus erythematosus | Biogen.
ClinicalTrials.gov.A study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS GO).
ClinicalTrials.gov.Exploring the efficacy and safety of CS20AT04 (allogenic bone marrow-derived stem cell) in systemic lupus erythematosus patients.
BioGen.Biogen announces first patient dosed in phase 3 systemic lupus erythematosus study | Biogen.
Clinicaltrials.gov.A study to evaluate the efficacy and safety of BIIB059 in adult participants with active systemic lupus erythematosus receiving background nonbiologic lupus standard of care (TOPAZ-1).
MedlinePlus.Belimumab Injection.
Benlysa.For subcutaneous use – BENLYSTA injection.
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?
